Loading organizations...
Denmark-based Fuse Vectors develops a cell-free enzymatic platform designed to manufacture high-quality adeno-associated virus vectors for the global gene therapy industry. The organization's proprietary system replaces traditional cell-based manufacturing processes to deliver over 99 percent filled capsids. This alternative approach provides pharmaceutical clients with improved purity, consistency, and scalability to accelerate the clinical development of new genetic treatments. Operating with dedicated research and development facilities located in the Netherlands, the enterprise has already established approximately a dozen early-stage partnerships with various gene therapy developers. The startup recently emerged from stealth mode after securing $5.2 million in pre-seed financing from institutional investors, including venture capital firm HCVC and the BioInnovation Institute, an initiative backed by the Novo Nordisk Foundation. Fuse Vectors was founded in 2022 by Jordan Turnbull, Benjamin Blaha, and Henrik Stage.
Fuse Vectors has raised $5.0M across 1 funding round.
Fuse Vectors has raised $5.0M in total across 1 funding round.
Fuse Vectors has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $5M Seed | — | Boutique Venture Partners, Hardware Club, Pioneer Fund, Republic Capital, Y Combinator | Announced |
Fuse Vectors has raised $5.0M in total across 1 funding round.
Fuse Vectors's investors include Boutique Venture Partners, Hardware Club, Pioneer Fund, Republic Capital, Y Combinator.
# Fuse Vectors: Redefining Gene Therapy Manufacturing
Fuse Vectors is a biotech startup developing cell-free technology to manufacture adeno-associated virus (AAV) vectors for gene therapy applications.[1] The company addresses a critical bottleneck in the gene therapy industry: current cell-based AAV production methods are slow, expensive, and produce inconsistent quality.[2] Fuse's solution replaces traditional cell-based manufacturing with a precise enzymatic system that produces high-quality AAV capsids in a single step, delivering over 99% filled capsids with superior purity and consistency.[2]
The company serves pharmaceutical and biotech partners developing gene therapies, enabling them to accelerate drug discovery and development timelines while reducing manufacturing costs. By unlocking manufacturing constraints that previously limited AAV variant screening and testing, Fuse positions itself as a foundational technology platform for the expanding gene therapy market.[3]
Fuse Vectors was founded in 2022 by Jordan Turnbull and Benjamin Blaha, both with backgrounds in pharmaceuticals and biotechnology.[3] The two initially set up a small laboratory using family funding while living off savings to develop their cell-free AAV assembly process.[3] They sought support from the BioInnovation Institute in Copenhagen, Denmark, a startup incubator financed by the Novo Nordisk Foundation, which provided crucial early backing.[3]
The founding team was later joined by Henrik Stage, and the three officially cofounded Fuse Vectors.[3] The company emerged from stealth approximately one year before February 2025, and by late 2024 had matured sufficiently to establish a relationship with venture capital firm HCVC, securing $5.2 million in funding.[3] The company has since established R&D operations in the Netherlands to accelerate its gene therapy innovation.[4]
Fuse Vectors operates at the intersection of two powerful trends: the explosive growth of gene therapy as a treatment modality and the industry-wide push to modernize biomanufacturing infrastructure. Over hundreds of clinical trials now employ viral vectors like AAVs to deliver therapeutic genes directly into cells, representing a fundamental shift from symptomatic treatment to potential cures.[2]
However, the manufacturing infrastructure supporting this innovation wave remains outdated. Traditional cell-based AAV production creates a critical bottleneck that constrains the pace of drug development and limits which indications can be economically pursued.[3] Fuse's technology directly addresses this constraint, effectively removing a major barrier to gene therapy commercialization. By enabling faster, cheaper, and more consistent AAV production, the company influences the broader ecosystem by making gene therapy development accessible to a wider range of organizations and indications.[1]
The timing is particularly significant: as gene therapy moves from niche applications toward mainstream pharmaceutical development, manufacturing capacity and efficiency become competitive advantages. Fuse's platform technology positions it as foundational infrastructure for the industry's next phase of growth.
Fuse Vectors is well-positioned to become a critical enabling technology in gene therapy development. The company currently maintains approximately a dozen early-stage partnerships and is actively seeking additional collaborations.[3] As these partnerships mature and move toward clinical development, demand for Fuse's manufacturing platform should accelerate.
The company's trajectory will likely be shaped by several factors: the pace at which its partners advance gene therapies through clinical trials, the company's ability to scale manufacturing to commercial volumes, and broader regulatory acceptance of cell-free manufacturing processes for therapeutic applications. If successful, Fuse could fundamentally reshape how the gene therapy industry manufactures its core products—transforming a historical constraint into a competitive advantage for early adopters of the platform.
